Engitix Secures $25M to Advance Cancer, Fibrosis Therapies
January 11, 2026, 3:38 am
British biotech innovator Engitix recently secured a significant $25 million Series A extension. Netherton Investments, acting for Mike Platt, drove this key financing. The capital fuels Engitix’s advanced extracellular matrix (ECM)-targeted therapeutic pipeline. Focus areas include solid tumors and various fibrotic diseases, promising new treatment avenues. Engitix leverages one of the largest proprietary ECM datasets globally. This data-driven platform accelerates preclinical development. Its strategy integrates translational biology and drug development. Existing strategic partnerships, notably with Dompé farmaceutici and Takeda, bolster its research. This investment signals robust confidence in the European biotech landscape. It underscores sustained investor interest in novel, targeted therapeutics across oncology and fibrosis, cementing Engitix's position in a thriving sector.
London-based Engitix closed a pivotal $25 million Series A extension. This financing bolsters its innovative drug development efforts. Netherton Investments provided the capital. Mike Platt, a prominent financial figure, backs Netherton. The funds will advance Engitix’s unique therapeutic pipeline. It targets the extracellular matrix (ECM) to combat serious diseases.
Engitix focuses on cancer and fibrosis. These conditions represent significant unmet medical needs. The company develops transformative therapies. Its approach centers on understanding the ECM. This complex network surrounds cells. It plays a crucial role in disease progression. Modulating the ECM offers new treatment avenues.
The British biotech integrates large-scale ECM datasets. It combines this with translational biology. Drug development follows. This creates differentiated therapeutics. They act within specific disease tissue microenvironments. Engitix aims to build a robust pipeline. Its platform identifies disease-associated signatures.
Preclinical development will accelerate. Engitix has proprietary ECM-targeted programs. Solid tumors are a key focus. Fibrosis programs also advance. The company seeks to improve patient outcomes meaningfully. Its platform continues to expand. It leverages extensive ECM data.
Strategic partnerships strengthen Engitix’s position. A drug discovery partnership exists with Dompé farmaceutici. Development collaborations are active with Takeda. These alliances target advanced fibrotic liver diseases. Such collaborations validate Engitix’s scientific approach. They also accelerate its therapeutic programs.
The investment reflects strong confidence. Netherton Investments sees compelling strategy. Engitix stands at the intersection of data, biology, and drug development. Support continues for its programs. Fibrosis and solid tumors remain primary targets. The capital infusion is a clear endorsement.
This funding event occurs within a dynamic European biotech landscape. The year 2025 saw sustained capital deployment. Oncology and fibrosis received significant attention. Mid-to-late-stage funding was particularly robust. Engitix’s $25 million round fits this broader pattern.
Comparable rounds underscore market vitality. TargED Biopharmaceuticals in the Netherlands secured €21.5 million ($25.5 million). It advanced targeted thrombotic disease therapies. FoRx Therapeutics in Switzerland raised €42 million ($49.9 million). Their focus is DNA-repair cancer therapies. Adcytherix in France obtained €105 million ($124.7 million). This supports novel antibody-drug conjugates. Tubulis in Germany attracted €308 million ($365.9 million). It expanded its ADC pipeline. These large raises highlight investor appetite for oncology innovation.
The United Kingdom remains a vibrant biotech hub. Trogenix secured €80 million ($95 million). This accelerates cancer treatments. Scripta Therapeutics raised over €10 million ($11.9 million). It supports their drug discovery platform. Engitix is part of this active British biotech cluster. UK companies attract substantial investment.
Other European countries also saw significant activity. Italy-based NanoPhoria received €83.5 million ($99.2 million). This funds a heart-failure therapy. Ireland’s Aerska secured €17 million ($20.2 million). It develops RNAi medicines for brain diseases. The diversity of funding shows wide-ranging biotech progress.
Collectively, these rounds represent massive investment. Over €600 million ($712 million) in disclosed biotech funding occurred in 2025. This indicates strong, sustained investor interest. Therapeutic platforms remain attractive. Companies developing novel approaches against complex diseases thrive.
Engitix was founded in 2016. Its mission targets the ECM. The company aims to redefine treatment paradigms. This new funding ensures continued progress. It enables further research and development. Patients facing cancer and fibrosis stand to benefit. The future of ECM-targeted therapies looks promising.
London-based Engitix closed a pivotal $25 million Series A extension. This financing bolsters its innovative drug development efforts. Netherton Investments provided the capital. Mike Platt, a prominent financial figure, backs Netherton. The funds will advance Engitix’s unique therapeutic pipeline. It targets the extracellular matrix (ECM) to combat serious diseases.
Engitix focuses on cancer and fibrosis. These conditions represent significant unmet medical needs. The company develops transformative therapies. Its approach centers on understanding the ECM. This complex network surrounds cells. It plays a crucial role in disease progression. Modulating the ECM offers new treatment avenues.
The British biotech integrates large-scale ECM datasets. It combines this with translational biology. Drug development follows. This creates differentiated therapeutics. They act within specific disease tissue microenvironments. Engitix aims to build a robust pipeline. Its platform identifies disease-associated signatures.
Preclinical development will accelerate. Engitix has proprietary ECM-targeted programs. Solid tumors are a key focus. Fibrosis programs also advance. The company seeks to improve patient outcomes meaningfully. Its platform continues to expand. It leverages extensive ECM data.
Strategic partnerships strengthen Engitix’s position. A drug discovery partnership exists with Dompé farmaceutici. Development collaborations are active with Takeda. These alliances target advanced fibrotic liver diseases. Such collaborations validate Engitix’s scientific approach. They also accelerate its therapeutic programs.
The investment reflects strong confidence. Netherton Investments sees compelling strategy. Engitix stands at the intersection of data, biology, and drug development. Support continues for its programs. Fibrosis and solid tumors remain primary targets. The capital infusion is a clear endorsement.
This funding event occurs within a dynamic European biotech landscape. The year 2025 saw sustained capital deployment. Oncology and fibrosis received significant attention. Mid-to-late-stage funding was particularly robust. Engitix’s $25 million round fits this broader pattern.
Comparable rounds underscore market vitality. TargED Biopharmaceuticals in the Netherlands secured €21.5 million ($25.5 million). It advanced targeted thrombotic disease therapies. FoRx Therapeutics in Switzerland raised €42 million ($49.9 million). Their focus is DNA-repair cancer therapies. Adcytherix in France obtained €105 million ($124.7 million). This supports novel antibody-drug conjugates. Tubulis in Germany attracted €308 million ($365.9 million). It expanded its ADC pipeline. These large raises highlight investor appetite for oncology innovation.
The United Kingdom remains a vibrant biotech hub. Trogenix secured €80 million ($95 million). This accelerates cancer treatments. Scripta Therapeutics raised over €10 million ($11.9 million). It supports their drug discovery platform. Engitix is part of this active British biotech cluster. UK companies attract substantial investment.
Other European countries also saw significant activity. Italy-based NanoPhoria received €83.5 million ($99.2 million). This funds a heart-failure therapy. Ireland’s Aerska secured €17 million ($20.2 million). It develops RNAi medicines for brain diseases. The diversity of funding shows wide-ranging biotech progress.
Collectively, these rounds represent massive investment. Over €600 million ($712 million) in disclosed biotech funding occurred in 2025. This indicates strong, sustained investor interest. Therapeutic platforms remain attractive. Companies developing novel approaches against complex diseases thrive.
Engitix was founded in 2016. Its mission targets the ECM. The company aims to redefine treatment paradigms. This new funding ensures continued progress. It enables further research and development. Patients facing cancer and fibrosis stand to benefit. The future of ECM-targeted therapies looks promising.